HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Offloads Popular German OTCs To PharmaSGP

Executive Summary

GSK divests non-core German OTC portfolio to local player PharmaSGP, which says it has gained "established brands" in the pain-relief and sleep-aid categories.

You may also be interested in...

EU Business News: Ceres Acquires GlobiFer Iron Supplement, PharmaSGP Achieves Record Quarter

The latest European consumer healthcare business news: Belgium's Ceres Pharma expands its portfolio with GlobiFer; and PharmaSGP achieves its best ever quarter thanks to the recovery of the OTC market.

Germany’s PharmaSGP Predicts Market Turnaround Despite Difficult First Half

Germany's PharmaSGP blamed ongoing lockdowns for falling first-half sales, but said it could see light at the end of the tunnel, with the OTC market expected to recover in the second half of the year.

GSK Hits Consumer Brand Divestment Target As Q3 Performance Mixed

GSK's Brian McNamara says the firm has hit its £1bn brand divestment target which will help fund the restructuring of its Consumer Healthcare business before it is spun off in 2022.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts